NMRA vs TXT · $283.5M cap vs P/E 19, rev $13.70B
Neumora Therapeutics, Inc. (NMRA) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
NMRA does not have a complete income-statement cache yet.
Latest reported TXT revenue for 2024-12-28 was $13.70B. Net income was $824.0M. Revenue was up 0.1% from 2023-12-30 to 2024-12-28. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
NMRA currently screens at market cap $283.5M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the NMRA and TXT stock pages for the full models.
Not investment advice.